Hims & Hers Reports Q1 Net Loss and Lower EBITDA, Raises Full-Year Revenue Guidance Amid GLP-1 Pivot
HIMS sits 91% above its 52-week low of $13.74.
Summary
Hims & Hers Health reported a Q1 net loss and lower Adjusted EBITDA, but raised its full-year revenue guidance, emphasizing its strategic pivot into branded GLP-1 products.
Key Events · Earnings and Guidance · HIMS
-
Q1 2026 Financial Performance
The company reported Q1 2026 revenue of $608.1 million, a 4% increase year-over-year. However, it swung to a net loss of $92.1 million from a net income of $49.5 million in Q1 2025, and Adjusted EBITDA declined significantly to $44.3 million from $91.1 million.
-
Full-Year 2026 Guidance Raised for Revenue
Hims & Hers raised its full-year 2026 revenue guidance to a range of $2.8 billion to $3.0 billion. Full-year Adjusted EBITDA guidance was updated to a range of $275 million to $350 million.
-
Strategic Pivot to Branded GLP-1 Products
Management highlighted a strategic pivot to expand its assortment of branded GLP-1 products, noting early demand signals show meaningful consumer reach broadening. This follows recent news and an 8-K filing on March 11, 2026, regarding a collaboration with Novo Nordisk.
-
Subscriber Growth Continues
Subscribers grew to nearly 2.6 million in Q1 2026, representing a 9% increase year-over-year, indicating continued customer acquisition despite profitability challenges.
Analysis · HIMS · Industrial Applications And Services
Hims & Hers Health reported a significant shift to a net loss and a substantial decline in Adjusted EBITDA for Q1 2026 compared to the prior year. This profitability hit is a key concern for investors. However, the company simultaneously raised its full-year revenue guidance, projecting accelerated growth, and highlighted its strategic expansion into branded GLP-1 products. This indicates a trade-off where current profitability is impacted by investments and strategic shifts, but management expects stronger top-line growth in the future, particularly from the high-demand GLP-1 market. Investors will be weighing the immediate profitability challenges against the positive revenue outlook and strategic direction.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.7% of the 1072 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.61%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HIMS was trading at $26.30 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $13.74 to $70.43. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.